文献速递免疫规划传染病防控与疫情报告

脂质体递送减毒活基孔肯雅病毒疫苗RNA基因组的加强免疫方案可保护小鼠抵抗基孔肯雅病毒病

A booster regime of liposome-delivered live-attenuated CHIKV vaccine RNA genome protects against chikungunya virus disease in mice.
PubMed 文献 · Vaccine · 2023-05-23

研究用CAF01脂质体递送减毒活基孔肯雅病毒疫苗CHIKV-NoLS的RNA基因组,对C57BL/6小鼠进行三剂肌内或皮下接种。皮下接种小鼠产生高水平中和抗体,三剂方案保护小鼠抵抗基孔肯雅病毒攻击所致的疾病体征和肌肉骨骼炎症;单剂减毒活疫苗CHIKV-NoLS可诱导长达71天的持久保护性免疫应答。

要点

  • 单剂CHIKV-NoLS CAF01未能提供系统性保护且抗体水平低。
  • 三剂CHIKV-NoLS CAF01肌内或皮下接种可诱导系统性免疫应答。
  • 皮下接种三剂方案的小鼠产生高水平基孔肯雅病毒特异性中和抗体。

核心结论

  • 临床相关的CHIKV-NoLS CAF01加强免疫方案可克服既往单剂策略的挑战,提供针对基孔肯雅病毒病的系统性保护。

研究设计与样本

  • C57BL/6小鼠分别经肌内或皮下接种三剂CHIKV-NoLS CAF01,并以CHIKV-NoLS单剂接种作为对照。

主要发现

  • 单剂CHIKV-NoLS CAF01未能提供针对CHIKV攻击的系统性保护,且CHIKV特异性抗体水平低。
  • 三剂CHIKV-NoLS CAF01接种小鼠产生与CHIKV-NoLS接种相似的系统性免疫应答,皮下接种小鼠产生高水平CHIKV特异性中和抗体。
  • 三剂CHIKV-NoLS CAF01接种小鼠在CHIKV攻击后免受疾病体征和肌肉骨骼炎症。
  • 单剂减毒活CHIKV-NoLS接种小鼠产生长达71天的持久保护性免疫应答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mosquito-transmitted chikungunya virus (CHIKV) is the causal pathogen of CHIKV disease and is responsible for global epidemics of arthritic disease. CHIKV infection can lead to severe chronic and debilitating arthralgia, significantly impacting patient mobility and quality of life. Our previous studies have shown a live-attenuated CHIKV vaccine candidate, CHIKV-NoLS, to be effective in protecting against CHIKV disease in mice vaccinated with one dose. Further studies have demonstrated the value of a liposome RNA delivery system to deliver the RNA genome of CHIKV-NoLS directly in vivo, promoting de novo production of live-attenuated vaccine particles in vaccinated hosts. This system, designed to bypass live-attenuated vaccine production bottlenecks, uses CAF01 liposomes. However, one dose of CHIKV-NoLS CAF01 failed to provide systemic protection against CHIKV challenge in mice, with low levels of CHIKV-specific antibodies. Here we describe CHIKV-NoLS CAF01 booster vaccination regimes designed to increase vaccine efficacy. C57BL/6 mice were vaccinated with three doses of CHIKV-NoLS CAF01 either intramuscularly or subcutaneously. CHIKV-NoLS CAF01 vaccinated mice developed a systemic immune response against CHIKV that shared similarity to vaccination with CHIKV-NoLS, including high levels of CHIKV-specific neutralising antibodies in subcutaneously inoculated mice. CHIKV-NoLS CAF01 vaccinated mice were protected against disease signs and musculoskeletal inflammation when challenged with CHIKV. Mice given one dose of live-attenuated CHIKV-NoLS developed a long lasting protective immune response for up to 71 days. A clinically relevant CHIKV-NoLS CAF01 booster regime can overcome the challenges faced by our previous one dose strategy and provide systemic protection against CHIKV disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rao S, Abeyratne E, Freitas JR, et al. A booster regime of liposome-delivered live-attenuated CHIKV vaccine RNA genome protects against chikungunya virus disease in mice. Vaccine. 2023. PMID: 37230889. doi:10.1016/j.vaccine.2023.05.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。